Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.

SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize the safety, tolerability, and pharmacokinetics of NPM-139 including a Wegovy® (semaglutide injection) group.